These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32629143)

  • 41. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.
    Yoshioka K; Matsue Y; Yamaguchi T; Kitai T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Kuroda S; Matsumura A; Hirao K
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):597-605. PubMed ID: 31218508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
    Ozawa T; Hashiguchi Y; Yagi T; Fukushima Y; Shimada R; Hayama T; Tsuchiya T; Nozawa K; Iinuma H; Ishihara S; Matsuda K
    Int J Colorectal Dis; 2019 Oct; 34(10):1731-1739. PubMed ID: 31478086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes.
    Lo KB; Toroghi HM; Salacup G; Jiang J; Bhargav R; Quintero E; Balestrini K; Shahzad A; Mathew RO; McCullough PA; Rangaswami J
    Rev Cardiovasc Med; 2021 Mar; 22(1):199-206. PubMed ID: 33792263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting.
    Kim J; Park J; Lee JH; Min JJ; Lee SH; Lee YT; Kim WS; Song S; Yeo JH; Cho H
    Sci Rep; 2020 Feb; 10(1):1716. PubMed ID: 32015422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
    Marciniak TA; Serebruany V
    Am J Med; 2019 Dec; 132(12):e844-e845. PubMed ID: 30871921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
    González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
    Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription in patients with chronic heart failure and multimorbidity attended in primary care.
    Frigola-Capell E; Verdú-Rotellar JM; Comin-Colet J; Davins-Miralles J; Hermosilla E; Wensing M; Suñol R
    Qual Prim Care; 2013; 21(4):211-9. PubMed ID: 24041138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis.
    Wu Z; Zhang H; Jin W; Liu Y; Lu L; Chen Q; Zhang R
    PLoS One; 2015; 10(6):e0129747. PubMed ID: 26083525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort.
    Lee S; Kim H; Woo Yim H; Hun-Sung K; Han Kim J
    J Appl Biomed; 2023 Apr; 21(1):7-14. PubMed ID: 37016775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.
    Carubelli V; Lombardi C; Specchia C; Peveri G; Oriecuia C; Tomasoni D; Di Pasquale M; Inciardi R; Garrafa E; Metra M
    ESC Heart Fail; 2021 Jun; 8(3):1944-1953. PubMed ID: 33660949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
    Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
    Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).
    AlJaroudi WA; Refaat MM; Habib RH; Al-Shaar L; Singh M; Gutmann R; Bloom HL; Dudley SC; Ellinor PT; Saba SF; Shalaby AA; Weiss R; McNamara DM; Halder I; London B;
    Am J Cardiol; 2015 Apr; 115(7):924-31. PubMed ID: 25682436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
    Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
    Diabetes Res Clin Pract; 2013 Dec; 102(3):233-41. PubMed ID: 24183258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ACEi/ARBs associate with lower incidence of gastrointestinal bleeding in peritoneal dialysis patients.
    Xie Y; Zhu L; Wang Z; Zhan X; Peng F; Feng X; Zhou Q; Wu X; Wang X; Su N; Tang X; Zhang Y; Zeng Y; Li M; Liang J; Liu L; Wen Y
    Clin Exp Nephrol; 2022 Mar; 26(3):278-285. PubMed ID: 34698915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
    Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.